Department of Respiratory Diseases, Reims University Hospital, Reims, France.
INSERM UMR-S 1250 "Pathologies Pulmonaires Et Plasticité Cellulaire," University of Reims Champagne-Ardenne, Reims, France.
Medicine (Baltimore). 2023 Jan 13;102(2):e32473. doi: 10.1097/MD.0000000000032473.
Pomalidomide is an immunomodulatory imide drug used in multiple myeloma and in Kaposi sarcoma.
A 72-years-old male, treated for multiple myeloma with dexamethasone, pomalidomide and daratumumab, presented dyspnea, hypoxemia, biological inflammatory syndrome, ground glass opacities on computed tomography scan (CT-scan) and lymphocytic and eosinophilic alveolitis, with no specific cytologic or microbiological findings, 2 months after pomalidomide initiation.
Antibiotics were started after bronchoscopy. No improvement was noted in dyspnea and biological inflammatory syndrome after 5 days of treatment. Pomalidomide was then discontinued, with continuation of Daratumumab-Dexamethasone, resulting in a rapid recovery of symptoms and CT-scan anomalies. No recurrence of dyspnea was observed during the 15 months of follow-up.
Pomalidomide-induced lung injury.
Pomalidomide-induced lung injury is a rare and serious adverse event that can occur early after Pomalidomide introduction. As pomalidomide use is increasing, the identification of drug toxicity as a possible cause of lung injury appears important. We report a rapid recovery of symptoms and CT-scan anomalies after pomalidomide discontinuation.
泊马度胺是一种免疫调节亚胺类药物，用于多发性骨髓瘤和卡波西肉瘤。
一名 72 岁男性，接受地塞米松、泊马度胺和达雷妥尤单抗治疗多发性骨髓瘤，在泊马度胺治疗 2 个月后出现呼吸困难、低氧血症、生物炎症综合征、计算机断层扫描（CT 扫描）呈磨玻璃样混浊和淋巴细胞性及嗜酸性肺泡炎，无特定细胞学或微生物学发现。
支气管镜检查后开始使用抗生素。治疗 5 天后，呼吸困难和生物炎症综合征无改善。随后停用泊马度胺，继续使用达雷妥尤单抗-地塞米松，症状和 CT 扫描异常迅速恢复。在 15 个月的随访中，未观察到呼吸困难复发。
泊马度胺引起的肺损伤。
泊马度胺引起的肺损伤是一种罕见且严重的不良反应，可在泊马度胺使用早期发生。随着泊马度胺的使用增加，确定药物毒性是否为肺损伤的可能原因显得尤为重要。我们报告了泊马度胺停药后症状和 CT 扫描异常迅速恢复。
